Gilead Sciences Inc 

GILD:NASDAQ

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
55.18 -1.18   -2.09%0.00%3,341,40714.2M

Market data is delayed by at least 20 minutes.
As of 10:44 AM ET 5/16/2013
 
 
 

Latest News Headlines for Gilead Sciences Inc

Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
16 hours 26 minutes ago - BusinessWire via Dow Jones News
-- Regimen Achieves 97 Percent Overall Response Rate with Estimated Progression-Free Survival at 24 Months of 93 Percent -- -- Results from Study 101-08 and Other Idelalisib Clinical Studies to Be Presented at American Society of Clinical Oncology Annual Meeting --
Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
1 days 18 hours 51 minutes ago - BusinessWire via Dow Jones News
Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif.--(BUSINESS WIRE)--May 14, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 27, 2013
This report contains detailed information about the company's business finances and management.
10-Q
May 8, 2013
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Bid/Size
-- / --
Ask/Size
-- / --
Price Open
56.60
Previous Close
56.36
Day High
56.64
Day Low
54.90
52wk High/Date
57.10 / 5/15/2013
52wk Low/Date
24.12 / 6/5/2012
% off 52wk High
-3.36%
% off 52wk Low
128.77%
Beta (5 Yr)
0.5
Market Capitalization
84.2B
Shares Outstanding
1.5B
Volatility Avg
29.31
EPS(TTM)
1.51
P/E Ratio
36.6x
Dividend Announcement
--
Dividend Yield
0.00%
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 5/16/2013 10:41 AM ET
 
 
 

GILD Gilead Sciences Inc vs. Peers

Peers 
GILD
Gilead Sciences Inc
53.46%
Abbott Laboratories
20.17%
Merck & Co., Inc.
14.14%
Pfizer Inc.
17.87%
GILD
Gilead Sciences Inc
0.00%
Abbott Laboratories
1.49%
Merck & Co., Inc.
3.68%
Pfizer Inc.
3.25%
GILD
Gilead Sciences Inc
-2.09%
Abbott Laboratories
-1.51%
Merck & Co., Inc.
-0.94%
Pfizer Inc.
-0.57%
Compare these stocks